NCT06978699View on ClinicalTrials.gov

A Phase II Study Evaluating the Efficacy and Safety of XH-S003 Capsules in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

August 30, 2025

Study Completion Date

October 30, 2026

Conditions

PNH - Paroxysmal Nocturnal Hemoglobinuria

Interventions

DRUG

XH-S003 Capsule

25mg \& 100mg

Trial Locations (1)

Unknown

RECRUITING

TianJin Medical University General Hospital, Tianjin

All Listed Sponsors

lead

S-INFINITY Pharmaceuticals Co., Ltd

INDUSTRY

NCT06978699 - A Phase II Study Evaluating the Efficacy and Safety of XH-S003 Capsules in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) | Biotech Hunter | Biotech Hunter